Gabapentin: A Viewpoint by Brett R. Stacey

ISSN： 1172-7047

Source： CNS Drugs, Vol.17, Iss.13, 2003-01, pp. : 983-984

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lubiprostone: A Viewpoint by Lawrence R. Schiller

By Schiller Lawrence R.

Drugs, Vol. 66, Iss. 6, 2006-01 ,pp. : 880-881

Adis International

Access to resources Recommend Favorite

Losartan: A Viewpoint by Donald R. Studney

By Studney D.R.

Drugs, Vol. 63, Iss. 4, 2003-01 ,pp. : 415-416

Adis International

Access to resources Recommend Favorite

Pioglitazone: A Viewpoint by John R. Petrie

By Petrie J.R.

Drugs, Vol. 60, Iss. 2, 2000-08 ,pp. : 344-345

Adis International

Access to resources Recommend Favorite

Galantamine Extended Release: A Viewpoint by Martin R. Farlow

By Farlow Martin R.

CNS Drugs, Vol. 20, Iss. 8, 2006-01 ,pp. : 682-683

Adis International

Access to resources Recommend Favorite

Intravenous Conivaptan: A viewpoint by Steven R. Goldsmith

By Goldsmith Steven R.

American Journal of Cardiovascular Drugs, Vol. 8, Iss. 5, 2008-01 ,pp. : 349-349

Adis International

Access to resources Recommend Favorite